New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:12 EDTHSP, DANOYHospira to obtain financial benefits from possible Danone deal, says Wells Fargo
After multiple media sources reported that Hospira (HSP) is in talks to buy Danone's (DANOY) medical nutrition business in a potential tax inversion deal, Wells Fargo estimates that the deal could be 9%-12% accretive to Hospira's EPS in 2015-2017 if it's an all-stock deal and 20%-22% accretive if it's a 50%/50% cash and stock deal. The firm The firm estimates that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from its current forecast of 24%-26% during those years. The firm thinks the strategic rationale for the deal from Hospira's perspective, however, is less clear. It keeps a Market Perform rating on the stock.
News For HSP;DANOY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
06:44 EDTDANOYDanone backs 2014 organic growth target of 4.5%
Backs 2014 trading operating margin down less than 20 basis points like-for-like. Backs 2014 free cash flow to be between EUR1.3B-EUR1.4B. Danone said it will continue to expand capacity rapidly and build development platforms in fast-growing regions, particularly Asia and Africa. Investments made for this purpose over the past two years have resulted in a higher use of debt than in the past, at a level that could imply a credit rating one notch lower, and that is appropriate for this current period of development given the companyís sound cash-flow outlook and debt structure.
06:42 EDTDANOYDanone to keep Medical Nutrition business, Reuters reports
Subscribe for More Information
December 11, 2014
07:13 EDTDANOY, HSPDanone to discuss whether to keep or sell medical nutrition unit, Reuters says
According to a source, Danone (DANOY) will hold a board meeting today to discuss whether to keep or sell its medical nutrition business, Reuters reports. Previous reports said Danone's board would decide whether to sell the unit to Hospira (HSP) or Fresenius (FMS), with Fresenius as the possible front-runner to enter exclusive talks. Reference Link
December 9, 2014
13:08 EDTHSPMerck may have paid $2B-$3B too much for Cubist, analyst says
Subscribe for More Information
08:23 EDTHSPMerck has 'no way out' of Cubist deal after court decision, says Leerink
Subscribe for More Information
08:12 EDTHSPMerck still sees Cubist acquisition neutral to modestly accretive to 2015 EPS
Merck (MRK) issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist (CBST) will create strong fundamental value for Merckís shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1B of revenue to its 2015 base, with strong growth potential thereafter. The courtís decision does not change Merckís expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a percentage basis to non-GAAP EPS in 2016, and will continue to be accretive thereafter.
December 8, 2014
19:00 EDTHSPCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:24 EDTHSPOn The Fly: After Hours Movers
Subscribe for More Information
18:00 EDTHSPCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTHSPFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTHSPMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTHSPJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
08:21 EDTHSPMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use